Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: A randomized controlled trial Academic Article uri icon

Overview

MeSH Major

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Anti-HIV Agents
  • HIV Infections

abstract

  • HIV-1 Immunogen with unrestricted ART failed to demonstrate an increase in HIV progression-free survival. JAMA. 2000;284:2193-2202.

publication date

  • November 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11056590

Additional Document Info

start page

  • 2193

end page

  • 202

volume

  • 284

number

  • 17